Biogen (HAM:IDP) Cyclically Adjusted Revenue per Share: €68.76 (As of Mar. 2026)


HAM:IDP Biogen Inc HAM:IDP
74 GF Score
Price €171.86
GF Value €165.52
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Biogen Cyclically Adjusted Revenue per Share?

Biogen HAM:IDP -1.13% 74 Cyclically Adjusted Revenue per Share is €68.76 as of Mar. 2026. GuruFocus rates HAM:IDP with a GF Score™ of 74/100 and a GF Value™ of €165.52 (Fairly Valued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biogen's adjusted revenue per share for the three months ended in Mar. 2026 was €14.443. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €68.76 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Biogen's average Cyclically Adjusted Revenue Growth Rate was 3.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biogen was 53.80% per year. The lowest was 5.10% per year. And the median was 21.20% per year.

As of today (2026-07-13), Biogen's current stock price is €171.86. Biogen's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €68.76. Biogen's Cyclically Adjusted PS Ratio of today is 2.50.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 11.12. The lowest was 1.45. And the median was 4.87.


Biogen  (HAM:IDP) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biogen's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=171.86/68.76
=2.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biogen was 11.12. The lowest was 1.45. And the median was 4.87.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biogen Cyclically Adjusted Revenue per Share Related Terms


Biogen Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Biogen's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Cyclically Adjusted Revenue per Share Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.89 64.14 67.58 73.86 68.58

Biogen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.29 68.26 67.55 68.58 68.76

HAM:IDP vs OGN, AMRN, SCLX: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Biogen's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Cyclically Adjusted PS Ratio falls into.


HAM:IDP
74GF Score
Biogen Inc HAM:IDP
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=14.443/330.2130*330.2130
=14.443

Current CPI (Mar. 2026) = 330.2130.

Biogen Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 11.740 241.018 16.085
201609 12.004 241.428 16.418
201612 12.547 241.432 17.161
201703 12.172 243.801 16.486
201706 12.911 244.955 17.405
201709 12.192 246.819 16.311
201712 13.175 246.524 17.648
201803 11.995 249.554 15.872
201806 13.860 251.989 18.163
201809 14.597 252.439 19.094
201812 15.483 251.233 20.350
201903 15.678 254.202 20.366
201906 16.811 256.143 21.672
201909 17.746 256.759 22.823
201912 18.552 256.974 23.839
202003 18.478 258.115 23.639
202006 20.319 257.797 26.027
202009 18.234 260.280 23.133
202012 15.216 260.474 19.290
202103 14.859 264.877 18.524
202106 15.345 271.696 18.650
202109 15.895 274.310 19.134
202112 16.403 278.802 19.428
202203 15.575 287.504 17.889
202206 16.753 296.311 18.670
202209 17.497 296.808 19.466
202212 16.517 296.797 18.377
202303 15.843 301.836 17.332
202306 15.580 305.109 16.862
202309 16.374 307.789 17.567
202312 14.998 306.746 16.145
202403 14.443 312.332 15.270
202406 15.695 314.175 16.496
202409 15.207 315.301 15.926
202412 16.067 315.605 16.811
202503 15.339 319.799 15.839
202506 15.635 322.561 16.006
202509 14.681 324.800 14.926
202512 13.153 324.054 13.403
202603 14.443 330.213 14.443

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €68.76 mean?
Biogen (HAM:IDP) has a Cyclically Adjusted Revenue per Share of €68.76 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biogen and its competitors.
Is Biogen's Cyclically Adjusted Revenue per Share too high?
Biogen's current Cyclically Adjusted Revenue per Share is €68.76. Overall, Biogen has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biogen's Cyclically Adjusted Revenue per Share compare to OGN and AMRN?
Biogen's Cyclically Adjusted Revenue per Share of €68.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Biogen and its competitors. Biogen's current Cyclically Adjusted Revenue per Share is €68.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Based on GuruFocus' analysis, Biogen (HAM:IDP) is currently considered Fairly Valued. The stock's GF Value™ is €165.52, compared to a current price of €171.86 — trading 3.8% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €68.76. Biogen's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Biogen (HAM:IDP), the current Cyclically Adjusted Revenue per Share is €68.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (HAM:IDP) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of €171.86 is trading 3.8% above its estimated GF Value™ of €165.52. GuruFocus considers Biogen to be Fairly Valued.

Key valuation signals for HAM:IDP:

  • Cyclically Adjusted Revenue per Share: €68.76
  • GF Value™: €165.52 vs. price of €171.86 (3.8% above fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the HAM:IDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
74GF Score

Get the complete analysis for HAM:IDP

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€171.86
Price
€165.52
GF Value